Calidi Biotherapeutics

Calidi Biotherapeutics Inc. is a clinical-stage immuno-oncology company that focuses on developing innovative therapies to treat cancer. The company operates in the biotechnology sector and primarily serves patients suffering from high-grade gliomas and solid tumors. Calidi Biotherapeutics utilizes proprietary technology that combines allogeneic stem cells with oncolytic viruses, such as the vaccinia virus and adenovirus, to create potent therapeutic platforms. These platforms are designed to arm the immune system to fight cancer more effectively. The company's business model revolves around advancing a series of ready-to-use product candidates through clinical trials, aiming for regulatory approval and subsequent commercialization. Revenue is generated through the development and potential future sales of these groundbreaking oncology treatments. Calidi Biotherapeutics is committed to pioneering new frontiers in cancer treatment by merging cutting-edge stem cell technologies with engineered viruses to attack cancer cells. Keywords: immuno-oncology, allogeneic stem cells, oncolytic viruses, high-grade gliomas, solid tumors, vaccinia virus, adenovirus, clinical-stage, biotechnology, cancer treatment.